***Background.*** Genital HSV-2 infection causes recurrent genital lesions and frequent viral shedding; current therapies do not completely control viral replication and require daily antiviral therapy. The therapeutic vaccine GEN003 contains 2 HSV-2 proteins, gD and ICP4, and Matrix M2 adjuvant (MM) to promote both B and T cell immune responses.

***Methods.*** We conducted a randomized, placebo controlled clinical trial in which 143 participants with genital HSV-2 infection were randomized to receive 3 vaccinations with 10, 30 or 100 µg of GEN003 with or without MM, or placebo. Participants collected twice daily swabs of genital secretions to assess genital shedding, and recorded genital lesions for 28 days prior to, immediately after; and 6 and 12 months after completion of vaccinations. Safety, immunogenicity and efficacy were monitored.

***Results.*** Immediately after vaccination, viral shedding in the 30 µg and 100 µg with MM groups decreased from baseline (rate ratios \[RR\] 0.47 and 0.68, respectively; p \< 0.001 for both). Shedding was unchanged from baseline for the placebo (RR= 1.01), unadjuvanted GEN003 (RR= 1.40), and 10 µg with MM groups (RR = 1.01). Shedding remained suppressed for the 30 µg with MM dose group at 6 months (RR = 0.57; p \< 0.001). Lesion rates were reduced after vaccination for the 30 and 100 µg with MM dose groups (RR 0.42 and 0.35, respectively; p \< 0.001 for both) and at 6 months for the 30 µg with MM dose (RR = 0.26; p \< 0.001). In a preliminary data review, at 12 months, lesion rates for the 30 µg with MM dose remained reduced (9.6% \[n = 29\] at baseline versus 2.4% \[n = 17\] at 12 months). Three participants in the 10 µg with MM group discontinued dosing due to adverse events. Injection reactions were previously reported (Wald, ICAAC 2013). Other than reactogenicity, the number (%) of participants who reported 1 or more other Grade 3 or 4 AEs considered related to vaccination by treatment group were: 10 µg with MM, 3 (10%); 30 µg with MM, 2 (7%); 100 µg with MM, 1 (4%); GEN003 without adjuvant 1 (4%); Placebo, 0 (0%).

***Conclusion.*** The antiviral effect of GEN003 persisted for at least 6 months with an effect on genital lesions up to 12 months. Immunotherapy with GEN003 may be an effective strategy, with or without traditional antiviral agents, to treat chronic genital HSV-2 infections.
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